Results 41 to 50 of about 40,684 (247)

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors

, 2015
Pontus B Persson Institute of Vegetative Physiology, Berlin, GermanyApixaban and rivaroxaban are oral factor Xa inhibitors. In a recent issue of Clinical Pharmacology: Advances and Applications, Frost et al compare apixaban (2.5 mg, twice daily) to ...
Persson PB
core  

Cold Gas Plasma Induces Platelet Activation and Hemostasis in Native and Anticoagulated Human Blood

Advanced NanoBiomed Research, EarlyView.
Cold physical gas plasma induces platelet activation and hemostatic responses in native and anticoagulated human blood. Treatment efficacy depends on plasma parameters, including gas composition, distance, and exposure mode, which govern reactive species delivery and energy transfer.
Sander Bekeschus, Broder Poschkamp, Lea Miebach, Anke Schmidt, Linus Hübner, Julia van der Linde   +5 more
wiley   +1 more source

Reversing factor Xa inhibitors – clinical utility of andexanet alfa

, 2017
Scott Kaatz,1 Hardik Bhansali,1 Joseph Gibbs,2 Robert Lavender,3 Charles E Mahan,4 David G Paje5 1Division of Hospital Medicine, 2Department of Internal Medicine, Henry Ford Hospital, Detroit, MI, 3Division of General Internal Medicine, University of ...
Gibbs J, Kaatz S, Bhansali H, Lavender R, Mahan CE, Paje DG   +5 more
core  

Factor Xa Acts as a PDGF-Independent Mitogen in Human Vascular Smooth Muscle Cells

, 2000
SummaryThis study investigates the mitogenic effect of the coagulation factor Xa in smooth muscle cells (SMC) from human saphenous vein and the procoagulant activity of these cells.
Michael Wittpoth, Marina Braun, Ellen Bretschneider, Annett Fischer, Erika Glusa, Karsten Schrör   +5 more
core   +1 more source

A prospective series of acute rivaroxaban overdose, coagulopathy and bleeding complications (ATOM 11)

British Journal of Clinical Pharmacology, EarlyView.
Aim There is limited research describing rivaroxaban overdose. We aim to describe rivaroxaban overdose, coagulopathy and bleeding complications. Methods This is a prospective series of acute adult (>14 years) rivaroxaban overdose presentations >40 mg enrolled in the Australian Toxicology Monitoring study and presenting to three Australian clinical ...
Katherine Z. Isoardi, Angela L. Chiew, Keith Harris, Geoffrey K. Isbister   +3 more
wiley   +1 more source

Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage.

BACKGROUND Patients with acute intracerebral hemorrhage who are receiving factor Xa inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that reverses the effects of factor Xa inhibitors, on hematoma volume expansion ...
Kallmuenzer, B, Sharma, M, Toni, Danilo, Ekholm, Ella, Lang, W, Seiffge, David J., Bereczki, D, Robinson, Thompson G., Connolly, Stuart J., Lindgren, Arne G, Crowther, Mark, Lang, Wilfried, Gumbinger, C, Czlonkowska, A, Demchuk, Andrew M, Himmelmann, Anders, Veltkamp, Roland, Taylor, A, Verhamme, P, Tsivgoulis, G, Shoamanesh, A, Sandset, Else Charlotte, Cohen, AT, Ladenvall, P, Ekholm, E, Law, Andrew, Verhamme, Peter, Demchuk, Andrew M., Connolly, SJ, Knutsson, Mikael, Taylor, Amanda, Tanne, David, Robinson, Thompson G, Poli, Sven, Xu, LZ, Coutinho, Jonathan M, Xu, Lizhen, Molina, Carlos A, Law, A, Tsiplova, K, Himmelmann, A, Bereczki, Daniel, Roine, Risto O, Milling, TJ, Lemmens, R, Seiffge, David J, Roine, RO, Gumbinger, Christoph, Amarenco, Pierre, Seiffge, DJ, Sandset, EC, Tanne, D, Toni, D, Cohen, Alexander T, Christensen, H, Beyer-Westendorf, Jan, Kallmünzer, Bernd, Knutsson, M, Lindgren, Arne G., Roine, Risto O., Coutinho, Jonathan M., Sharma, Mukul, Molina, CA, Ladenvall, Per, Shoamanesh, Ashkan, Robinson, TG, Cohen, Alexander T., Connolly, Stuart J, Lemmens, Robin, Middeldorp, Saskia, Demchuk, AM, Karyakina, T, Tedim Cruz, V, Coutinho, JM, Veltkamp, R, ANNEXA-I Investigators, Mikulik, Robert, Christensen, Hanne, Lindgren, AG, Middeldorp, S, Amarenco, P, Becattini, Cecilia, Beyer Westendorf, J, Crowther, M, Mikulik, R, Tsiplova, Kate, Karyakina, Tetyana, Członkowska, Anna, Tedim-Cruz, Vitor, Tsivgoulis, Georgios, Milling, Truman John, Molina, Carlos A., Poli, S   +92 more
core   +1 more source

A Study on the Effects of Dırect Factor Xa Inhibitors and Direct Thrombin Inhibitors on Human Primary Chondrocyte Cultures [PDF]

, 2019
Aim:This study investigates the effects of two direct factor Xa inhibitors, apixaban and rivaroxaban, and a direct thrombin inhibitor, dabigatran, on human primary chondrocyte cultures.Materials and Methods:Monolayer cultured chondrocytes were prepared ...
Duygu YASAR SIRIN, Numan KARAARSLAN, Hanefi OZBEK, Yasin Emre KAYA, Hande AKALAN, İbrahim YILMAZ, Özkan ATES   +6 more
core  

Role of coagulation factor Xa and protease-activated receptor 2 in human mesangial cell proliferation

, 2005
Role of coagulation factor Xa and protease-activated receptor 2 in human mesangial cell proliferation.BackgroundFibrin deposition and mesangial cell proliferation are frequently observed in the active type of mesangioproliferative glomerulonephritis ...
Kasuno, Kenji, Liu, Ning, Takahiko Ono, Kita, Toru, Toru Kita, Fumiaki Nogaki, Nomura, Keiko, Misa Tanaka, Nogaki, Fumiaki, Tanaka, Misa, Kenji Kasuno, Ono, Takahiko, Ning Liu, Keiko Nomura, E.M.I. Oida, Oida, E.M.I., Arai, Hidenori, Hidenori Arai   +17 more
core   +1 more source

Harnessing blood clot as a native scaffold for orchestrating tissue repairs and regeneration

BMEMat, EarlyView.
The blood clot, owing to its dynamic composition and unique microenvironment, holds significant yet underappreciated potential for tissue engineering. This review systematically summarizes the pathophysiology of clot formation, the key regulatory factors shaping its microenvironment, and its applications in both pre‐clinical and clinical settings ...
Gao‐peng Dang, Yu‐zhu Wang, Yi‐fei Wang, Que Bai, Jia‐xin Hao, Zhi‐ting Li, Xiao‐qing Cao, Yu Wei, Yue Feng, Ji‐hua Chen, Franklin R. Tay, Rui‐bing Wang, Jun‐ting Gu, Li‐na Niu   +13 more
wiley   +1 more source

Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications

, 2018
Linda Tahaineh,1 Sahar M Edaily,1 Shadi F Gharaibeh2 1Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology (JUST), Irbid, Jordan; 2Department of Pharmaceutical Sciences, Faculty of Pharmacy, Jerash University,
Tahaineh L, Edaily SM, Gharaibeh SF
core